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ABSTRACT OF THESIS 
 
DEVELOPMENT AND CHARACTERIZATION OF NOVEL MONOCLONAL 
ANTIBODIES FOR STUDYING PRION PATHOGENESIS 
 
Monoclonal antibodies (mAbs) recognizing different regions of PrP are potential 
tools in the study of prion diseases and immunotherapy. We used shuffled 
recombinant prion protein containing elk and mouse PrP as antigen to produce 
monoclonal antibodies in mice. We found that mAb 5C6 mapped to a 
discontinuous epitope comprised of amino acid 132 and 158 (mouse numbering). 
Monoclonal anibody 9E9 which maps to a unique N-terminal epitope at amino 
acid preferentially recognized cervid PrP. In contrast, the epitope of mAb 9H9 is 
located in the C-terminus and only reacted with mouse and hamster. The epitope 
for mAb 7H11 appears to be affected by the glycosylation of PrP and by the 
presence or absence of the disulfide bond. To confirm the epitopes of these mAbs, 
we constructed elk and mouse mutants both with and without reactivity to 5C6 
and 9E9. We then used these mutants to investigate the effect of each epitope on 
the conversion of PrPC to PrPsc. In one approach to map the epitopes of 
newly-generated monoclonal antibodies (mAbs), we generated a series of 
contiguous ten amino acids deletion constructs spanning amino acids 107 to 230 
and expressed these recombinant proteins in mammalian cells (RK13) or 
bacteria. Using Western blotting, all deletion constructs could be recognized with 
antibodies to the extreme C-terminus of PrP, or the N-terminal region upstream of 
the structured globular domain of PrP. However, mAb 5C6 failed to react with all 
internally deleted PrP constructs expressed in mammalian cells, and to a lesser 
extent bacterially produced mutant recombinant proteins. We confirmed the 
surprising result using the well-defined antibodies 6H4 and D18, which recognize 
epitopes in the same internal region as 5C6. Our results suggest the formation of 
an ultra-stable, SDS-resistant conformation in PrP harboring deletions mutations 
in the globular domain of PrP. We hypothesize that epitope burying within this 
stable conformation(s) precludes mAb recognition by 5C6, 6H4 and D18. It will be 
of extreme interest to determine the relationship of this previously undefined PrP 
conformation to the pathogenic process of PrP conformational change. 
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Chapter 1 
Introduction 
 
The Prion diseases 
Prion diseases, also called transmissible spongiform encephalopathies 
(TSEs), are a group fatal neurodegenerative diseases occurring in humans and 
animals.  They are characterized by the development of spongiform 
degeneration associated with neuronal loss, reactive astrocytic gliosis, and 
occasionally amyloid deposition in the brains of infected hosts.  The cause of 
prion diseases is an unconventional proteinaceous pathogen termed prion 
(Prusiner 1982).  Unlike other infectious agents, the prion is resistant to many 
physical and chemical treatments such as Ultraviolet irradiation, heat or 
nucleases that are usually used to inactivate conventional pathogens.  After such 
treatments, the infectivity of prions is not reduced (Alper, Cramp et al. 1967; Gibbs, 
Gajdusek et al. 1978; Prusiner 1982). Currently, no therapies or cures are 
available.  
 
Prion diseases of humans are unique in that they can be inherited in an 
autosomal dominant manner, occur sporadically, or result from infection. The 
human diseases include Creutzfeldt-Jacob disease (CJD), kuru, fatal familial 
insomnia (FFI), Gerstmann-Straussler-Scheinker disease (GSS), and variant CJD 
(vCJD).  Approximately 85% of human prion disease are sporadic CJD which 
occurs at a frequency of one to two cases per million people per year, usually 
between the age of fifty to sixty years (Wadsworth J.D.F. 2007).  Kuru was the 
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first recognized that transmissible human prion disease.  Kuru occurs in the fore 
linguistic group of eastern the highlands province of Papua New Guinea where 
they have ritualistic cannibalism (Gajdusek, Gibbs et al. 1967).  Children and 
women, who were the main consumers of elder tribe members’ brains, were most 
often affected by kuru (Alpers and Gajdusek 1965).  Several familial human prion 
diseases exist including FFI and GSS.  These diseases account for 10% to 20% 
of all human prion diseases. The age of clinical onset in familial prion diseases is 
generally earlier, and the incubation time is longer than in sporadic prion diseases 
(Collinge, Whitfield et al. 2008).  In the 1990s, several cases of CJD, termed 
variant Cretuzfeld-Jakob disease (vCJD), were recognized in young adults, 
generally in their early twenties, with a clinical presentation in which behavioral 
and psychiatric disturbances predominated. Biochemical and neuropathological 
data indicated a possible association with bovine spongiform encephalopathy 
(BSE) in cattle (Bruce, Will et al. 1997; Hill, Desbruslais et al. 1997).  To date with 
approximately 200 individuals have developed disease, most of the cases were 
occurred in Great Britain.  This unique feature has allowed retrospective studies 
designed to determine the true frequency of disease, which suggests than many 
more individuals are incubating the disease than have currently developed clinical 
symptoms worldwide (Ironside, Hilton et al. 2000).  At present, there is a concern 
that some individuals exposed to BSE might be asymptomatic carriers of 
infectivity (Brandel, Delasnerie-Laupretre et al. 2000) and that these people might 
pose a risk of further transmission of the infection to others (e.g., blood 
transfusions, donors for corneal transplantations)   
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In animals, prion diseases can either occur naturally or as the result of 
consumption of contaminated food and are more common than in humans.  In 
1986, a new prion disease occurring in cattle of United Kingdom was termed 
Bovine spongiform encephalopathy (BSE).  BSE is amplified through the bovine 
food chain via eating feed containing rendered meat and bone meal contaminated 
with bovine brain and spinal cord from infected cattle (Wilesmith, Ryan et al. 
1991).  This disease has affected cattle worldwide after the first case in United 
Kingdom.  In 1996, a variant CJD has been reported in humans (Will, Ironside et 
al. 1996).  Extensive biochemical and pathogenetic evidence indicated that 
vCJD is caused by consumption of with BSE-contaminated food.      
 
Chronic Wasting Disease (CWD) which was first discovered at a research facility 
in north central Colorado in 1967 is a TSE affecting mule-deer (Williams and 
Young 1980), Rocky Mountain elk (Williams and Young 1982), white-tailed deer 
(Spraker, Miller et al. 1997), black-tailed deer (Williams and Young 1980), and 
moose (Baeten 2007).  This disease was identified as a TSE by identification of 
neuronal vacuoles (Williams and Young 1980) and deposition of plaques or 
aggregated prion protein in the brain (Spraker, Zink et al. 2002)  These animals 
contained prion infectivity in the brain (Williams and Young 1992; Browning, 
Mason et al. 2004) and in skeletal muscle (Angers, Browning et al. 2006).  CWD 
has rapidly spread to several states including New York and West Virginia from a 
small region in southeastern Wyoming, northeastern Colorado, southwestern 
Nebraska, and a small part of Canada (Sigurdson 2007).  It has also been found 
in imported elk in South Korea (Sohn, Kim et al. 2002).  The distribution of the 
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disease in focal spots suggests the possibility that outbreaks may have occurred 
as a result of spillover from infected game farms rather than spread as a result of 
the natural movement of free-ranging animals (Sigurdson 2007).  CWD is the 
only prion disease of wild animals that has been documented to be transmitted 
horizontally.  The source and route of transmission are currently unknown (Miller, 
Wild et al. 1998; Miller, Williams et al. 2000).  Additionally, CWD is highly 
contagious between cervids.  However its ability to transmit to other species is 
not entirely clear, especially to those that share lands with CWD-affected cervids 
or to humans consuming the meat of CWD-affected animals.  
 
Scrapie is a natural prion disease of sheep and has existed over 200 years with 
no evidence suggesting transmission to humans despite the existence of several 
well-characterized strains (Bruce 1993).  There are multiple environmental 
sources of infection to transmit between sheep or flocks.  Transmissible Mink 
Encephalopathy (TME) is a prion disease of mink that has been found 
sporadically in farmed mink in several countries.  It was first recognized in 1947 
in Wisconsin and Minnesota (Eckroade 1973).  TME has been experimentally 
transmitted to several species including cattle (Hamir 2006), sheep and goats 
(Hadlow 1987), monkeys (Eckroade 1970), skunks and ferrets (Eckroade 1973), 
and raccoons (Eckroade 1973; Hamir, Miller et al. 2004).  The most interesting 
transmission of TME is from an affected mink in Wisconsin to hamsters.  After 
serial passage, it presents with two distinct clinical profiles termed hyper (HY) and 
drowsy (DY) (Bessen and Marsh 1992).  These two strains of TME were found 
with different transmission profiles and biochemical properties in hamsters 
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(Bessen and Marsh 1992).  
 
Molecular biology of prion proteins (PrPC and PrPSc) 
The normal form PrP, cellular prion protein (PrPC), is a molecule ubiquitously 
expressed in mammalian cells.  It is synthesized in the secretory pathway on 
endoplasmic reticulum (ER)-attached ribosomes as a 253 amino acid protein 
before post-translational modification.  Mature PrPC is found as a glycosyl 
phosphatidyl inositol (GPI) –linked glycoprotein with a disulfide bond which is 
enriched in cell membrane and is highly conserved in mammals.  The N-terminal 
region of this molecule is unstructured, but it still contains two defined and 
conserved regions.  The first region consists of five repeats amino acid 
sequence called octa-repeat region (Riek, Hornemann et al. 1997; Smith, Drake 
et al. 1997).  This region has been proposed to be important in copper binding 
and might be involved in prion pathogenesis (Brockes 1999).  The second region 
contains a highly hydrophobic profile, which was originally termed transmembrane 
region 1(Hay, Barry et al. 1987; Shyng, Moulder et al. 1995).  The function of this 
domain is still unclear, but it is relevant to prion pathology and necessary for PrPC 
α-cleavage (Lutz, Brabeck et al. 2010).  The carboxyl terminus of PrPC contains 
of three α- helices, and two anti-paralleled β- sheets.  There are two asparagine 
residues that for glycosylation and two cysteine residues will form a disulfide bond 
links α-helices two and three (Riek, Hornemann et al. 1996; Prusiner 1998; Harris 
2003).  The pathogenic form PrP (PrPSc) is derived from PrPC and has identical 
amino acid sequence with PrPC (Oesch et al., 1985; Chesebro et al., 1985; Stahl 
et al., 1993).  
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PrPC is a high -helical content structure containing 42% -helix and 3% -sheet.  
When PrPSc is formed, some of the -helix is converted into β-sheet.  PrPSc is a 
high -sheet construct contains 43% -sheet increasing from 3% (Caughey, Dong 
et al. 1991; Pan, Baldwin et al. 1993; Pergami, Jaffe et al. 1996).  Because of this 
conformational transition, PrPSc has lower solubility in non-denaturing detergents, 
a high tendency to aggregate and partial resistance to proteinase K (PK).  Unlike 
PrPrSc, PrPC is PK sensitive and detergent soluble (Table 1).  Because of these 
properties, the protease resistance of PrP is a way to distinguish the two forms of 
PrP (Oesch, Westaway et al. 1985).  After treatment with PK, PrPSc is seen as 
three bands: the di-glycosylated, mono-glycosylated, and un-glycosylated form in 
western blot (Bolton, McKinley et al. 1982; Oesch, Westaway et al. 1985), while 
PrPC is degraded.  
 
Modification and trafficking in the cell 
The processing of mature PrPC includes the cleavage of the N-terminal signal 
sequence by a signal peptidase in the ER, removal of the C-terminal signal 
peptide and replacement with a glycosylphosphatidylinositol (GPI) anchor, 
formation of a disulfide bond between two cysteine residues, and glycosylation at 
two asparagines (Prusiner 1998; Harris 2003).  PrPC is then delivered to the cell 
surface and anchored to the outer leaflet of neurons and other cell types in lipid 
rafts via the GPI anchor (Figure 1).  PrPC is also recycled between the plasma 
membrane and endocytic compartment (Shyng, Huber et al. 1993).  PrPC is 
highly expressed on the surface of neurons and lymphocytes, but is also 
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expressed on dendritic cells and cells of the monocyte lineage (Kitamoto, 
Muramoto et al. 1991).  There are two other topological forms of PrPC that are 
both in the transmembrane.  One is found with the N-terminus in the lumen of the 
ER and is called Ntm-PrP and the other is in the opposite orientation and called 
Ctm-PrP (Hegde, Mastrianni et al. 1998).  Mature PrPC has a molecular weight of 
approximately 33-35kD containing an N-terminal unstructured flexible region with 
an octapeptide repeat that can bind copper and a C-terminal structured region 
with three alpha helices and two short beta sheets (Figure 1.1).   
 
Several studies indicate that the conversion of cellular PrPC to a protease 
resistant PrPSc is a posttranslational event that occurs after the protein reaches 
the lipid raft on the cell surface. (Caughey and Raymond 1991; Borchelt, 
Taraboulos et al. 1992; Taraboulos, Raeber et al. 1992).  The reason why PrPC 
has to reach the membrane before it converted to PrPSc is still unknown.  One 
possibility might be the posttranslational modifications for PrPC are necessary for 
its conversion after reaching the plasma membrane.  One possibility is PrPC 
functions as a receptor that mediates PrPSc internalization during infection.  
Alternatively the lipid and protein environment at the plasma membrane might be 
favorable for the PrPC and PrPSc interaction and conversion, or a factor needed 
for the transconformation could be localized specifically at the plasma membrane 
(Prusiner 1998; Campana, Sarnataro et al. 2005). 
 
When PrPC was transported to the cell surface, PrPC undergoes an 
endoproteolytic cleavage event The C1 cleavage site (Chen, Teplow et al. 1995) 
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is located between 109/110 in mouse sequencing numbering, producing a 
17-KDa C-terminal fragment.  When PrPC is converted to PrPSc, the 
conformational change of PrP makes the C1 cleavage site instead of a new 
cleavage site termed C2 cleavage producing a 21-Kda C-terminal fragment. The 
C2 cleavage site is between 88 and 89 in mouse numbering.   
 
Function of PrP 
PrPC has been found in several mammals, and is highly conserved (Harris, Lele et 
al. 1993; Windl, Dempster et al. 1995).  The expression of PrPC can be detected 
in most tissues except in kidney and liver, and is particularly high expressed in the 
central nervous system (Miele, Alejo Blanco et al. 2003).  PrPC is ubiquitously 
expressed, but its function still remains unknown.  Several groups have 
generated PrP knock out (Prnp-/-) mice in an effort to study the function of PrPC. 
In 1992, Büeler group in Zurich deleted the open reading frame of Prnp gene to 
create the Zurich I Prnp-/- mouse.  The resulting mice were devoid of PrPC and 
found to be developmentally normal (Büeler et al., 1992).  However, these mice 
do display demyelination in the peripheral nervous system with age, but without 
the development of clinical signs (Nishida et al., 1999). In 1994, another knock out 
mouse model of PrnP-/- (Edinbugh)  was generated and also developed normally 
(Manson, Clarke et al. 1994).  Later, there was another Prnp-/- mice developed by 
Sakaguchi group known as Prnp-/- (Nagasaki). This knockout mouse strain 
involved deleting the open reading frame of PrnP gene and ~1Kb of the intron 5’ 
to the open reading frame including the splice acceptor site (Moore et al., 1999; 
Sakaguchi et al., 1996).  This The deletion in the non coding region caused 
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unusual intergenic splicing between the remaining PrP gene and a Prnd gene 
encoding a protein called Doppel (Dpl), which is 16 kb downstream of the Prnp 
locus (Moore, Lee et al. 1999). Mice did develop ataxia and loss of cerebellar 
Purkinje cells with age (Sakaguchi, Katamine et al. 1996) but this was attributed to 
the overexpression of Doppel, not the absence of PrPC (Moore et al., 1999; 
Sakaguchi et al., 1996). The doppel protein shares 24% homology in amino acid 
sequence with PrP, is primarily expressed in the testis, and is absent in the CNS 
of wild type mice but present in the CNS of Nagasaki Prnp-/- mice (Silverman, Qin 
et al. 2000).  Several studies demonstrated PrPC is an important factor for 
developing Prion disease by examining the susceptibility of Zurich PrnP-/- mice to 
scrapie (Büeler, Aguzzi et al. 1993).  However, PrP knockout mice are resistant 
to prion disease after inoculation with prions (Büeler, Aguzzi et al. 1993; Prusiner, 
Groth et al. 1993). But susceptibility can be restored after introducing PrPC into 
these mice (Büeler, Aguzzi et al. 1993). These studies provide further evidence 
that PrPC is required for the conversion process and formation of PrPSc. 
 
Species Barrier  
The species barrier or transmission barrier was thought to be caused by 
differences in the primary sequence of host and donor PrP (Harris 1999; Horiuchi, 
Priola et al. 2000).  It refers to the restriction of transmission of prion diseases 
between different species.  It depends on the species being infected and the 
specific strain of TSE agent involved.  For example, mouse scrapie can be 
transmitted to Syrian hamsters with a long incubation time (over 370 days) but 
transmitted to mice with shorter incubation time (around 100 days) (Kimberlin and 
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Walker 1978).  The 263K hamster scrapie strain transmitted into Syrian 
hamsters has 60-day incubation time, but there is no clinical disease observed 
when it is transmitted to mice (Kimberlin, Walker et al. 1989). Mouse PrP and 
Syrian hamster PrP differ at only 12 of 209 amino acids.   There are many 
factors that influence the species transmission barrier. Understanding its 
molecular basis and mechanism is valuable after the discovery that vCJD is the 
result of a transmission of BSE from cattle to human (Collinge, Sidle et al. 1996; 
Hill, Desbruslais et al. 1997). It raises concerns about the possibility of 
transmission of prions from other species to humans, for example CWD from deer 
and elk.  The differences in primary sequence of PrP and prion strain are two 
factors that contribute to the species transmission barrier. 
 
Prion Strains and Polymorphisms 
Prion strains are characterized by difference of incubation time, distribution of 
pathological lesions that they produce in the central nervous system of recipient 
animals and clinical symptoms. (Telling 2004; Angers, Kang et al. 2010).  The 
influence of genetic variability on susceptibility to disease and pathogensis has 
been reported.  Susceptibility or resistance to scrapie in sheep is associated with 
polymorphisms at codons 136 (A/V), 154 (R/H) and 171 (Q/R/H) of the sheep 
Prnp gene (Elsen, Amigues et al. 1999).  Scrapie susceptibility is conferred by 
the VRQ and resistance by ARR and AHQ polymorphisms.  ARQ and ARH are 
with an intermediate situation.  The polymorphisms in all species of cervids are 
also currently investigated (Schatzl, Wopfner et al. 1997; O'Rourke, Baszler et al. 
1998; Johnson, Johnson et al. 2003; O'Rourke, Spraker et al. 2004; Jewell, 
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Conner et al. 2005; Johnson, Johnson et al. 2006; Green, Browning et al. 2007; 
Meade-White, Race et al. 2007).  One polymorphism found in elk is codon 132 
encoding either methionine or leucine (Schatzl, Wopfner et al. 1997; O'Rourke, 
Baszler et al. 1998).  This polymorphism is important because this residue 
corresponds to codon 129 in the human prion protein that has been shown the 
susceptibility to vCJD (Collinge, Sidle et al. 1996).   
  
Immunological approach to study prion diseases  
Several anti-PrP antibodies have been produced to detect prions and diagnose 
prion diseases via immunoblotting.  The similarity in the primary sequence of 
donor PrPSc in comparison to PrPC of the recipient species seems to play a crucial 
role in the species barrier.  The monoclonal antibody 3F4 recognized amino 
acids from position 109 to 112 in human PrP (Barry and Prusiner 1986; Kascsak, 
Rubenstein et al. 1987) and has been one of the most commonly used tools in 
studying prion disease.  It reacts strongly to human and hamster PrP and 
requires two methionine residues at position 109 and 112 in human PrP.  PrP 
from other species which lack one or both methionine residues does not react with 
3F4.  Some groups introduced 3F4 epitope into MoPrP by replacing leucine 108 
and valine 111 with methionines present in human and hamster PrP and have 
demonstrated the 3F4 required these two methionines for recognition.  However, 
because the epitope of 3F4 is close to the endoproteolytic processing site of PrP, 
the introduction of this tag partially interfered with the conversion process and 
substantially reduced the total consistent PrPSc accumulation in infected cells 
(Priola, Caughey et al. 1994; Lund, Olsen et al. 2007).  MAb L42 is another 
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antibody that reacts with PrPC in a broad range of species including sheep, cattle, 
goat, pig, human, dog, cat, mink, rabbit, and guinea pig but not mouse and 
hamster in immunoblotting analysis (Vorberg, Pfaff et al. 2000).  MAb L42 was 
raised by immunization of mice with an oligopeptide covering the ovine PrPC 
sequence 145-163 (corresponding to position 141-159 of murine PrP).  Some 
groups were using antibody-based immunotherapy against prion disease.  
However, the difficulty of using antibody to cure prion diseae in humans still needs 
to overcome is host tolerance to PrPC (White, Enever et al. 2003). 
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Thesis research 
 Monoclonal antibodies (mAbs) are indispensable in studying and diagnosing 
prion diseases.  It is also useful for immunotherapy.  The goal of this project is 
to produce and characterize novel monoclonal antibodies against PrP.  To 
achieve the goal we used PCR-based method to shuffle and generate a novel PrP 
structure containing mouse PrP and cervid PrP.  We will be utilizing these novel 
anti-PrP monoclonal antibodies to study the species barrier, conversion 
mechanism of PrPC to PrPSc, and the secondary structure conformation.   
The results section includes how we made a shuffled recombinant prion 
protein composed of mouse and elk PrP.  We used this mixed recombinant prion 
protein as antigen to produce novel monoclonal antibodies in PrP-null mice.  We 
used the feature of conserved PrP sequence of variant species to screen our 
hybridoma cells, we identified four monoclonal antibodies.  We found that mAb 
5C6 mapped to a discontinuous epitope comprised of amino acid 132 and 158 
(mouse numbering).  Monoclonal anibody 9E9 which maps to a unique 
N-terminal epitope at amino acid preferentially recognized cervid PrP.  In 
contrast, the epitope of mAb 9H9 is located in the C-terminus and only reacted 
with mouse and hamster.  The epitope for mAb 7H11 appears to be affected by 
the glycosylation of PrP and by the presence or absence of the disulfide bond.  In 
result section 2, in order to confirm the epitopes of these mAbs, we constructed 
elk and mouse mutants both with and without reactivity to 5C6 and 9E9.  We 
then used these mutants to investigate the effect of each epitope on the 
conversion of PrPC to PrPsc.  The results may provide new insights into the 
biology of PrPC and PrPSc.  
14 
 
 
In result section 3, it provides another approach to map monoclonal antibodies. 
We generated a series of contiguous ten amino acids deletion constructs 
spanning amino acids 107 to 230 and expressed these recombinant proteins in 
mammalian cells or bacteria.  Using Western blotting, all deletion constructs 
could be recognized with antibodies to the extreme C-terminus of PrP, or the 
N-terminal region upstream of the structured globular domain of PrP. However, 
mAb 5C6 failed to react with all internally deleted PrP constructs expressed in 
mammalian cells, and to a lesser extent bacterially produced mutant recombinant 
proteins.  We confirmed the result using the well-defined antibodies 6H4 and 
D18, which recognize epitopes in the same internal region as 5C6.  Our results 
suggest the formation of an ultra-stable, SDS-resistant conformation in PrP 
harboring deletion mutations in the globular domain of PrP.  We hypothesize that 
epitope burying within this stable conformation(s) precludes mAb recognition by 
5C6, 6H4 and D18.  It will be of extreme interest to determine the relationship of 
this previously undefined PrP conformation to the pathogenic process of PrP 
conformational change. 
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Figure 1.1 Schematic diagrams of mouse PrP primary structure and its 
posttranslational modifications.  The N-terminal region of PrP is unstructured 
and the C-terminal region is structured.  In the extreme N terminus is a secretory 
signal peptide (orange).  Region 51-90 consists of 5 octarepeats, which was 
suggested to play a role in copper binding (Brockes 1999).  The royal blue region 
is the structured region containing 3 -helices denoted 1, 2, 3 in red and two 
β-sheets denoted β1, β2 in red.  N-linked glycosylation site (Asn180, Asn196) is 
indicated by two red hexagons.  Cysteines 178 and 213 form a disulfide bridge.  
Glycosyl phosphatidyl inositol (GPI) anchor signal peptide is located at the end of 
C-terminus and labeled green.  There are two endoproteolytic cleavage sites, C1 
and C2, indicated by arrows.  C1 cleavage site is located at position 
His110/Val111 and will produce a ~17kDa C1 fragment. C2 cleavage site is 
located at position Trp88/Gln89 and will produce a ~21kDa C2 fragment.  
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Table 1. Comparison of PrP properties 
 
PrPC PrPSC 
Soluble Insoluble 
-helix rich -sheet rich 
Proteinase- sensitive Proteinase-resistance 
monomers aggregates 
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Chapter 2 
Materials and methods 
 
Preparation of antigen using DNA shuffling 
PCR amplification of elk and mouse PrP coding sequences:  100 ng of 
recombinant plasmids (pCAGGS-MoPrP or pCAGGS-elkPrP) carrying elk or 
mouse prion protein gene were amplified with pfu polymerase (Stratagene) as 
following condition: pre-denaturation 95°C/3min; 95°C /40sec; 60°C /40sec;72°C 
/60sec. PCR products were purified by running 1.2% agarose followed by column 
purification (Premega). The concentration of purified PCR products was quantified 
by running 1.2% agarose gel with DNA standard.  
DNase I digestion of mixed MoPrP and elkPrP DNA fragments: 3 μg of mixted 
PCR products of MoPrP and ElkPrP (1:1) was incubated at 15°C for 10 min, then 
add 0.15 unit of DNase I(Roche), incubated at 15°C for 10min, the reaction was 
terminated by adding 10μL of stop solution and inactivated DNase I at 96°C  for 
10min. The DNase I digested DNA was separated with 2% low-temperature 
agarose gel (Invitrogen) along with 10-bp DNA ladder. DNA fragments with the 
length from 10 to 300bp were purified with phenol/chloroform method.   
Re-assembly of small DNA fragments: 30 μL of DNase I digested DNA fragments, 
5 μL of Pfu Ultra buffer, 1μL of dNTP (Roche), 1μL of Pfu Ultra were mixed and the 
volume was adjusted to 50μL with ddH2O.  The re-assembly PCR were 
performed for 45 cycles as the following conditions: 94°C/3min; 94°C/30sec; (27°C 
+1°C/cycle) /1min; 72°C/(1min+4sec/cycle); the PCR product was maintained at 
72°C for 10min and then stored at 4°C.  
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PCR amplification of reassembled PCR products: The reassembled DNA 
fragments were amplified with primers with the addition of EcoRV and BamHI at 
5’ends of upstream or downstream primers for 35 cycles as the following 
conditions: pre-denaturation 94°C/3min; 94d°C/45sec; 47°C with increase 
0.7°C/cycle 1min; 72°C/1min. PCR products were kept at 72°C for 10min. The 
shuffled DNA fragments were digested, purified and then inserted into 
pIRESpuro3 vector.  
PCR-RFLP prescreening the chimeric DNA: Bacterial Colony-PCR was 
performed and PCR products were purified with Wizard DNA purification Kit 
(Promega) and digested with StuI and AluI.   
DNA sequencing: plasmids were extracted according to QIA miniprep protocol 
(Qiagen), and sequenced with CEQ8000 instrument. 
Cell cultures 
Rabbit epithelial kidney RK13 cells (ATCC, Manassas, VA) were maintained in 5% 
CO2 at 37 °C in DMEM with 10% FBS. 
Constructs 
The elk PrP or mouse PrP coding sequence was amplified by polymerase chain 
reaction (PCR) with primers containing AflII and EcoRI restriction endonuclease 
recognition sites at the 5’ and 3’ ends respectively. Digested amplicons were 
inserted into AflII- and EcoRI-cleaved pIRESpuro3 vector (Clontech, Mountain 
View, CA). Following confirmation of the elk PrP coding sequence in the 
recombinant vector, RK13 cells were transfected with pIRESpuro3 containing elk 
PrP, mouse PrP or empty vector to produce RKE, RKM and RKV cells 
respectively.  
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Generation of transfected cells  
Cells were plated in 6-well plates one day prior to transfection. Transfection 
mixtures were prepared by mixing 2 μg of plasmid and 6.3 μl of lipofectamine 
2000 (Invitrogen, Carlsbad, CA) in Opti-MEM medium (Invitrogen, Carlsbad, CA). 
Prior to addition of 200 μl transfection mixture, cells were rinsed with Opti-MEM. 
Following addition of transfection mixtures, 0.8 ml of complete medium containing 
10 % FBS was added to cell monolayers. Following passage to 10 cm plates 24 hr 
later, transfected cells were grown in complete medium containing 1 µg/ml 
puromycin. Selection medium was changed every 3 days.  
Infection with brain homogenate in Cell culture 
Cells (2 x 105) were split to 6 well plates one day before prion infection. 10 % brain 
homogenates diluted in Opti-MEM medium to 0.2 - 2% were added to cell 
monolayers, in a volume of 1 ml per well. After 5 h, 2 ml of Opti-MEM medium 
containing 15 % FCS was added. Cells were split into 10 cm plates, followed by 2 
more passages. Cell lysates were harvested at passage 3 for Western blotting. 
Immunoblotting   
RK13 Cell lysate: 
Cultured cell were treated with cold lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 
0.5% sodium deoxycholate, 0.5% Igepal CA-630) and total protein concentration 
was determined by bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc., 
Rockford, IL). Lysates were either untreated or treated with 40 mg/ml proteinase K 
(PK) for one hour at 50oC and the reaction was terminated with 4 mM phenyl 
methyl sulfonyl fluoride (PMSF) in final concentration. PrPSc in cell culture lysates 
was purified by centrifugation for 1 h at 100,000 x g at 4°C. Samples were boiled 
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in the presence of SDS for 10 min prior to electrophoresis. Proteins were 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) using 10% Tris-glycine gels, and electrophoretically transferred to 
PVDF-FL membranes (Millipore, Billerica, MA). Membranes were blocked in 
Tris-buffered saline with 0.05% Tween-20 and 5% non-fat milk, incubated with 
anti-PrP monoclonal antibody (mAb) 6H4 (Prionics AG, Schlieren-Zurich), or other 
in-house mAb followed by HRP-conjugated sheep anti mouse IgG secondary 
antibody. Membranes were developed using ECL-plus detection (Amersham), 
and analyzed by using a FLA-5000 scanner (Fuji).  
Brain homogenate: 
Animals whose death was obviously imminent were euthanized by CO2 inhalation 
and cervical dislocation. Brain tissues from sacrificed mice were isolated rapidly 
on dry ice and stored frozen at -80°C. Ten % brain homogenates in phosphate 
buffered saline (PBS) lacking calcium and magnesium ions were prepared on ice 
by repeated passage through 18-, followed by 22-gauge needles. 10 % brain 
homogenates were aliquoted and stored in -80°C. Total protein concentration was 
determined by bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc., 
Rockford, IL).  Equivalent amounts of total protein were boiled at 100oC in an 
equal volume of 4X sodium dodecyl sulfate (SDS) buffer (100 mM Tris HCl, 4% 
SDS, 0.2 % bromophenol blue, 20 % glycerol) for 10 minutes. Boiled samples 
were then electropheretically separated on a 12 % SDS-polyacrylamide gel 
(acrylamide, SDS, ammonium persulfate and TEMED - Bio Rad). PK digestion of 
brain homogenates were performed with the addition 2% sarkosyl and incubated 
for 1 hr at 37 °C at a PK concentration of 40 µg/ml.  Digestion was terminated by 
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the addition of phenyl methyl sulfonyl fluoride (PMSF) to a final concentration of 4 
mM.  Deglycosylation of PrP was achieved by digestion with recombinant 
PNGase F for 1 hour at 37°C, as specified by the supplier (New England Biolabs, 
Beverly, MA).  Following the addition of 4x non-reducing SDS loading buffer, 
samples were boiled for 10 minutes at 100 °C.  Proteins were resolved by 12% 
SDS-PAGE and electrophoretically transferred to polyvinylidene fluoride (PVDF) 
membranes for later development PVDF-FL membranes (Millopore) for 
fluorescent scanning.  Following electrophoretic transfer, membranes were 
incubated for 45 min in 5% (w/v) low fat milk in Tris buffered saline containing 
Tween 20 (TBST) to block non-specific protein binding.  Membranes were 
probed two hours at 4 °C with monoclonal antibody and incubated 1 hour at room 
temperature with horse raddish peroxidase (HRP)-conjugated goat anti-Mouse 
secondary antibody.  Blots were developed using ECL-Plus detection 
(Amersham Biosciences, Piscataway, NJ) and analyzed by using a FLA-5000 
scanner (Fuji). 
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Chapter 3 
Results 
 
Section 1: Production and Characterization of monoclonal antibodies 
 
A. Generating immunogen containing murine and cervid PrP using DNA 
shuffling 
Many anti-PrP antibodiest have been produced.  To create anti-PrP monoclonal 
antibodies with novel epitopes, we generated new PrP sequences by 
reassembling the sequences of two different species in vitro.  The similarity 
between mouse and elk PRNP coding sequence is 81.54% and protein similarity 
is 85.56% (Figure 2.1).  Dr. Jifeng Bian, a scientist in our laboratory, used 
polymerase chain reaction (PCR) to amplify mouse and elk PRNP coding 
sequences.  He digested the PCR products with DNase I to generate a random 
pool of fragments.  These fragments were reassembled by repeated cycles of 
annealing in the presence of DNA polymerase.  Some of these fragments were 
overlapping.  Recombination can occur when a fr fragment from one specie 
becomes the template for a fragment from the other, and vice versa, causing 
template switch (Stemmer 1994; Stemmer 1994).  With the resulting chimeric 
PrP constructs, we were able to produce a panel of antibodies which can 
recognize mouse PrP, elk PrP or both.  Roughly one hundred sequences 
containing mouse and elk PrP were produced. There are 30 amino acids which 
differ between mouse and elk PrP sequence. Three constructs, shuffled PrP #3, 
#34 and #68, with equal distribution of mouse and elk PrP sequence, were 
chosen for immunization.   In Figure 2.1, red squares represent mouse PrP 
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sequence and green squares represent elk PrP sequence.  The middle 
sequence is shuffled PrP #68, with mouse PrP sequence above and elk PrP 
sequence below for reference. Of the 30 amino acids which differ between mouse 
and elk, this chimera share 14 with mouse PrP and 16 with elk PrP.  
 
In order to generate recombinant shuffled protein, Dr. Hae-Eun Kang, a postdoc 
in our laboratory, cloned these three shuffled PrPs into pET-100/D-TOPO vector 
(Invitrogen) containing polyhistidine site and enterokinase (EK) recognition site in 
the N-terminus.  She utilized the polyhistidine site to purify recombinant protein 
with Ni-NTA resin.  After purification, she used EK, which cleaves at the 
C-terminus of the EK recognition site, to remove N-terminal tags without leaving 
extraneous amino acid residues on the shuffled protein (Figure 2.2).    
 
B. Screening of hybridoma cells 
Fusing myeloma cells with spleen cells from a mouse that has been immunized 
with the desired antigen is a popular method to produce monoclonal antibodies 
(Kohler and Milstein 1975).  In our study, we reassembled PrP sequences and 
chose three constructs containing an equal percentage of the elk and mouse PrP 
sequences.  We expressed these constructs in bacteria, purified them, and used 
them as immunogen.  In order to achieve an immune response, PrP-null mice 
(Prnp−/−) were used (Bueler, Fischer et al. 1992).  Each shuffled PrP was used to 
immunize two PrP-null mice.  Freund's complete adjuvant (CFA) was used to 
emulsify the antigen.  CFA is effective in stimulating immunity and may increase 
the production of immunoglobulins.  After immunization, we collected blood and 
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detected the immune response via enzyme-linked immunosorbent assay (ELISA).  
It was found that one mouse immunized with shuffled PrP #68 had an increased 
immunogenic response to PrP (Figure 2.3) and she spleen cells from this mouse 
were collected.  After fusion of spleen cells with myeloma cells, we selected a 
series of hybridoma cells producing monoclonal antibodies recognizing 
recombinant mouse PrP (rMoPrP) or elk PrP (rElkPrP) in the ELISA.  Screening 
of hybridomas revealed several antibodies that reacted strongly against 
recombinant PrP in the ELISA and western blot.  Four of the antibodies that had 
strong reactivity were picked for further characterization.  They are hybridoma 
cell lines 5C6, 9E9, 7H11 and 9H9.  
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Figure 2.1 Comparing primary structures of mouse PrP, elk PrP and shuffled 
PrP.  This figure is to show the different sequencing result between mouse and 
elk PrP in primary structure and the distribution of these two species PrP in the 
shuffled PrP #68.  The top is mouse PrP sequence and the bottom is elk PrP 
sequence. The middle sequence is our shuffled PrP #68. The difference between 
mouse and elk PrP is indicated by a red box (mouse) or a green box (elk). The 
amino acid sequence of shuffled PrP #68 was labeled as indicated. The 
numbering was designated in elk numbering. The locations of secondary structure 
are indicated by brown arrows (beta-sheet) and blue ribbons (alpha-helix).  
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Figure 2.2 SDS-PAGE analysis of purified shuffled PrP recombinant protein. 
‘E’ is eluted PrP with His in urea buffer at pH4.5. ‘Su’ is recombinant PrP in 
NaOAc buffer at pH5.9 after EK treatment. ‘Pt’ is precipitated recombinant PrP in 
NaOAc buffer at pH4.5 after EK treatment. ‘C’ is control without EK treatment. The 
PAGE was stained (a)coomassie blue, or blotted  with (b) mouse monoclonal 
antibody anti-PrP 6H4 with 1:10,000 dilution or (c) His-probe. 
  
27 
 
 
 
Figure 2.3 Titration of anti-PrP antibodies in the immunized mice. 96 well 
ELISA plate was coated with 100ul of 1µg/ml recombinant shuffled PrP solution 
per well. Blood serum was prepared from immunized mouse tails.  Color 
development was done with ABST peroxidase solution, and the absorbance of 
samples was measured at 405 nm in ELISA plate reader. The x-axis is the dilution 
factor of the serum. Blue Square indicates the response of one immunized mouse 
with shuffled PrP#68. Red triangle represented second mouse immunized with 
shuffled PrP#68. Grey triangle represents mAb 6H4 as a control. 
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C. Characterization of anti-PrP monoclonal antibodies 
To determine further specificity of the anti-PrP mAbs, western blot and 
immunohistochemical analyses were performed.  Mammalian PrP (being 95% 
conserved) has a higher homology of amino acid sequences as compared to PrP 
in other species (Oesch, Westaway et al. 1985; Robakis, Sawh et al. 1986).  To 
characterize these antibodies, we utilized transgenic (Tg) mouse brain 
homogenates, which were engineered to express PrPs from different species.  
Tg(MCerB+C) is a transgenic line containing mouse residues predicted to 
associate with hypothetical mouse protein X and cervid residues predicted to 
interact with PrPSc from cervids with CWD.  All brain homogenates were 
prepared with 10% w/v sterile PBS lacking Ca2+and Mg2+.  The total protein 
content was measured by bicinchoninic acid assay (BCA).  The non-diluted 
supernatant of the hybridoma cell culture was used as the first antibody.  The 
previously characterized anti-PrP monoclonal antibody (MAb) 6H4 (Korth, Stierli 
et al. 1997) was used as a positive control.  MAb 6H4 recognizes a single linear 
epitope, DYEDRYYRE, corresponding to positions 144–152 of human PrP.  The 
mAb 6H4 reacted with 10% brain homogenates from a broad range of various Tg 
mice (Figure 2.4).  
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Figure 2.4 Western blot analysis of various Tg mouse brain homogenates 
with 6H4. All Transgenic mouse brain homogenates were prepared with 10% w/v 
sterile PBS lacking Ca2+and Mg2+. Total protein content was measured by 
bicinchoninic acid assay (BCA). Each lane was loaded with 25 µg brain 
homogenate. KO is represented with Tg Prnp-/- background mice, and is a 
negative control. Tg(MoPrP)4112 expresses high levels of mouse PrP in the 
knockout background. Tg(DeerPrP)1536 expresses deer PrP on the knockout 
background whereas Tg(ElkPrP)5037 expresses elk PrP,  Tg(BoPrP)3705 
expresses bovine,  Tg(OvPrP-ARQ)3533 expresses one sheep allele of PrP, with 
arginine at residue 136 and Tg(OvPrP-VRQ)4166 expresses sheep PrPC with 
valine instead.  Tg(EqPrP)5525 expresses horse PrPc on knockout background.  
Tg(HuPrP-M129)6816 expresses human PrP with methionine at residue 129 in 
knockout background mouse whereas Tg(HuPrP-V129)7826 expresses  valine 
in residue 129.  Tg(MCerB+C)849, is a chimeric line which expresses the mouse 
residues predicted to associate with mouse protein X and the cervid residues 
predicted to interact with PrPSc from cervids with CWD. Membrane was probed 
with mAb 6H4 in 1:10000 dilution, a comercial anti-PrP monoclonal antibody.  
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1) Monoclonal Antibody 5C6 
To characterize the reactivity of 5C6 with PrP from different species, we prepared 
10% brain homogenates from Tg mice expressing various PrPC sequences 
including mouse PrP, deer PrP, elk PrP, bovine PrP, sheep PrP, equine PrP, and 
human PrP.  From the western blot analysis, mAb 5C6 did not react with sheep 
PrP(VRQ), which has a polymorphism at residue 136 with sheep(ARQ) (Figure 
2.5A).  According to Figure 2.4, there is PrP expression in the brain homogenate 
of sheep (VRQ).  Our collaborator, Dr. Jason Bartz, helped us to further 
characterize 5C6 by probing samples from his laboratory.  He found that mAb 
5C6 reacted with brain homogenates of a hamster, mink, ferret and cow, but did 
not react with a squirrel monkey brain homogenate (Figure 2.5B).  Based on the 
western blot analysis with Tg mouse homogenates and other mammals’ brain 
homogenates, 5C6 can efficiently recognize mouse, elk, deer, cow, sheep (ARQ), 
human and horse PrP.  Sheep (VRQ) and squirrel monkey have no reactivity 
with 5C6.  According to these results and comparing the primary structure of 
various mammals, the epitope of mAb 5C6 requires alanine and asparagine in 
positions 132 and 158 of mouse PrP, respectively. (Figure 2.6) 
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Figure 2.5 Western blot analysis to assess 5C6 epitope via brain 
homogenates of (A)Tg mice and (B)other mammals. (A) 25 µg transgenic 
mouse brain homogenate was loaded in each lane. KO is represented with Tg 
Prnp-/- background mice, and is a negative control. All abbreviations for the 
transgenic lines can be found in the previous figure legend. Membranes were 
probed with mouse monoclonal Ab 5C6. (B) From Bartz Lab. 500µg brain was 
loaded in each lane. Each lane is representative brain homogenate of hamster, 
mink, ferret, squirrel monkey or cow.   
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Figure 2.6 Prion protein sequence alignment of various mammals and 
shuffle PrP #68 in order to assess 5C6 epitope. Numbers at top indicate 
mouse number amino acid sequence. The black bar at the bottom indicates 
secondary structure, 1, 1 and partial 2 sequentially. Light blue shows one 
epitope of 5C6 at residue 132 in MoPrP, a polymorphism for ovine PrP.  The 
unique amino acid valine from sheep (VRQ) is labeled circled in red. The other 
epitope of 5C6 at residue 158 in MoPrP is indicated by royal blue. The unique 
amino acid, serine, from squirrel monkey PrP, is circled in red. 
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2) Monoclonal Antibody 9E9 
We also used 10% brain homogenates from Tg mice expressing various PrPC 
sequences to assess the epitope of the mAb 9E9.  Compared with 6H4 in Figure 
2.4, the mAb 9E9 reacted with 10% brain homogenates from Tg mice expressing 
deer PrP, elk PrP, bovine PrP, sheep PrP, and has weak binding to equine PrP.  
MAb 9E9 did not react with either mouse PrP, human PrP or Tg (MCerB+C) 
(Figure 2.7).  When we aligned the PrPC sequences from various species, we 
found two possible epitope regions for mAb 9E9.  One is located before the C2 
cleavage site, and the other one is between the C1 and C2 cleavage sites.  In 
order to assess the epitope of mAb 9E9, we removed Asn-linked glycans by 
treating brain homogenates with N-glycosidase F (PNGase F).  PNGase F is an 
amidase that cleaves the innermost GlcNAc from asparagine residues on 
N-linked glycoproteins.  If the epitope of 9E9 is located before the C2 cleavage 
site, we expected to detect the full length of PrP with 9E9 after PNGaseF 
treatment.  If the epitope of 9E9 is located between the C1 and C2 cleavage sites, 
we expected to detect the full length and C2 fragment of PrP with 9E9 after 
PNGaseF treatment.  To detect the PrP fragment after treatment with PNGase F, 
we used mAb 6H4 as a control.  MAb 6H4’s epitope lies between amino acid 
residues 144 and 152. We expected it would recognize full-length PrP, 21 kDa C2 
fragment, and 17kDa C1 fragment after treatment (Figure 2.8A).  In the western 
blot analysis, mAb 9E9 recognized full length PrP and the 21 kDa C2 fragment, 
but not the 17 kDa C1 fragment (Figure 2.8B).  According to the western blot 
analysis results, we confirmed 9E9 has no reactivity with mouse PrP and we 
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narrowed down the eiptope of mAb 9E9 to the C1 and C2 endoproteolytic 
cleavage sites from amino acid 89 to 109 in mouse numbering shown in the box 
(Figure 2.9).  Compared to the amino acids sequence of various species, mAb 
9E9 recognizes CerPrP sequence between C1 and C2 cleavage site but fails to 
recognize MoPrP due to the insertion of a glycine at positions 93 of MoPrP 
(Figure 2.9).  9E9 has weak binding reactivity with horse and sheep PrP 
compared to 6H4. Both horse and sheep PrP have a unique amino acid serine, at 
position 94 as compared to the other mammals which react with 9E9.  This might 
influence the reactivity of 9E9 with horse and sheep PrP.  
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Figure 2.7 Western blot analysis of assessing 9E9 epitope via brain 
homogenate of Tg mice. 40 µg transgenic mice brain homogenate was loaded in 
each lane. KO is represented with Tg Prnp-/- background mice, and is a negative 
control. Tg(MoPrP)4112 shows no reactivity with 9E9, nor does the chimeric 
Tg(MCerB+C) or the human lines, Tg(HuPrP-M129) and Tg(HuPrP-V129).  
Tg(DeerPrP,Tg(ElkPrP) and Tg(BoPrP) show reactivity with 9E9.  
Tg(OvPrP-ARQ), Tg(OvPrP-VRQ) and Tg(EqPrP) show reduced 9E9 binding.  
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Figure 2.8 Western blot analysis of effect of PrP processing on mAb 
reactivity.  Samples were either untreated (-) or treated (+) with PNGase F or 
proteinase K as indicated. FVB is a wild type mouse with endogenous PrP.  
Infected FVB is wild type mouse adapted RML. Tg(ElkPrP) is transgenic line 5037, 
expressing elk PrP in knockout background mouse. Infected Tg(ElkPrP) was 
Tg(ElkPrP) mouse adapted CWD isolate 092. PNG: PNGase F. PK: proteinase K. 
F: Full length of PrP; C2: 21kDa C2 fragment; C1: 17kDa C1 fragment. The blot 
was probed with (A) anti-PrP mAb 6H4 (B) anti-PrP mAb 9E9. The secondary 
antibody is anti-mouse in 1:5000 dilution. (performed by Eri Saijo) 
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Figure 2.9 Prion protein sequence alignment of various mammals and 
shuffle PrP #68 in order to assess 9E9 epitope. Numbers at top indicate mouse 
number amino acids sequence. The proteolytic cleavage sites are indicated with 
arrows. C1 cleavage site is between 110/111. C2 cleavage site is between 88/89.  
According to the western blot analysis of treatment with PNGase F, we narrowed 
down the epitope of mAb 9E9 as located between C1 and C2 cleavage sites. 
Glycine at position 93 in mouse and human PrP blocks the reactivity with 9E9. 
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3) Monoclonal Antibody 7H11 
To detect the reactivity of mAb7H11, we used the same 10% brain homogenates 
from Tg mice expressing various species PrPC.  MAb 7H11 reacted with mouse 
PrP, deer PrP, elk PrP, sheep PrP, equine PrP, human PrP and Tg (McerB+C), 
but did not react with bovine PrP (Figure 2.10).  The binding capacity of mAb 
7H11 with Tg(Hu-PrP) on western blot seems weaker than other species.  When 
comparing the bovine PrP sequence with other mammals PrP sequences, bovine 
PrP has a unique amino acid, glutamic acid, at residue 197 in bovine PrP 
numbering.  Because this glutmaic acid is located between two N-linked glycans, 
we think these two N-linked glycans might have a hindrance effect on the binding 
ability of 7H11.  In order to detect the effect between the reactivity of mAb 7H11 
and N-linked glycans, un-infected and infected Tg mouse brain homogenates 
were subjected to PNGase F or proteinase K treatment.  For infected brain 
homogenates treated with PK, we expected to see three bands; Di-glycosylated 
form, mono-glysylated form and un-glycosylated form PrP.  Comparing the lane 
loaded with infected brain homogenate treated with PK from Figures 2.11 A and B, 
we can observe that mAb 6H4 recognized three forms of PrP but mAb 7H11 failed 
to recognize the di-glycosylated form of PrP from infected brain homogenates 
after PK treatment.  This result indicates that the reactivity of mAb 7H11 is 
blocked by the presence of N-linked oligosaccharides.  The weak reactivity 
between mAb 7H11 and Tg(HuPrP) brain homogenate, is likely due to the 
presence of histidine in the human residue at the site homologous to  residue 
166 in bovine.  In the other species, as well as our shuffled immuogen, this 
residue is tyrosine.  Also, the amino acid of interest, glutamic acid, is located 
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thirty amino acids downstream of the sequence in the disulfide bond region.  We 
think the disulfide bond might be involved in the binding reactivity of mAb 7H11.  
To assess the effect of the disulfide bond, two sets of brain homogenate samples 
were prepared.  One set of samples was mixed with loading buffer containing 
reducing agent (2-Mercaptoethanol) the other set without.  Surprisingly, mAb 
7H11 had a stronger reaction with the samples lacking the reducing agent (Figure 
2.12).  Based on these two observations, I hypothesize the epitope of mAb 7H11 
is conformational and is sterically hindered by N-linked oligosaccharides.  To 
elucidate my hypothesis, I prepared four samples treated with reducing agent 
and/or PNGase F.  The presence of reducing agent did have an effect on mAb 
7H11 binding.  Samples that were not treated with reducing agent had a stronger 
reactivity with mAb 7H11 (Figure 2.13 A and B).  Removing the N-linked 
oligosaccharides via PNGase F (Fig2.13 C and D) had no effect on 7H11 binding 
capacity.  
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Figure 2.10 Western blot analysis of assessing 7H11 epitope via brain 
homogenate of Tg mice. Each lane was loaded with 50µg transgenic mice brain 
homogenate. KO is represented with Tg Prnp-/- background mice, and is a 
negative control. 7H11 reacted with mouse PrP, deer PrP, elk PrP, sheep PrP, 
equine PrP, and Tg (McerB+C), weakly with human PrP and did not react with 
bovine PrP. This blot is probed with hybridoma cell supernatant 7H11. The 
secondary antibody is anti-mouse in 1:5000 dilution. 
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Figure 2.11 Effect of PrP processing on mAb 7H11 reactivity. Samples were 
either untreated (-) or treated (+) with PNGase F or proteinase K as indicated.  
FVB is a wild type mouse with endogenous PrP.  Infected FVB is wild type 
mouse adopted RML. Tg(ElkPrP) is transgenic line 5037, expressing elk PrP in 
knockout background mouse. Infected Tg(ElkPrP) was Tg(ElkPrP) mouse 
adapted CWD isolate 092. PNG: PNGase F. PK: proteinase K. Di-: di-glycosylated 
form PrP; Mono-: mono-glycosylated form PrP; Un-: un-glycosylated form PrP.  
The blot was probed with (A) anit-PrP mAb 6H4 (B) anti-PrP mAb 7H11. The 
secondary antibody is anti-mouse in 1:5000 dilution. (performed by Eri Saijo) 
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Figure 2.12 Effect of reducing agent on 7H11 binding.  
In order to see the effect of reducing agent on 7H11 binding, samples were 
treated with or without beta-Mercaptoethanol. (A) Samples were not treated with 
beta-Mercaptoethanol and (B) Samples were treated with beta-Mercaptoethanol. 
KO refers to mice in which the prnp coding sequence is disrupted and express no 
PrPC, and is a negative control. All other transgenic lines are as previously 
described. 7H11 binding was stronger under non-reducing conditions. 10ul from 
10% brain homogenate 
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Figure 2.13 Effect of PrP processing and reducing agent on mAb 7H11 
reactivity. In order to see the effect of reducing agent and glycosylation site, 
samples were treated with reducing agent beta-Mercaptoethanol or PNGase F. 
KO refers to mice in which the prnp coding sequence is disrupted and express no 
PrPC, and is a negative control. FVB is indicated wild type mouse brain 
homogente. Tg(DeerPrP) is transgenic line 1536, expressing deer Prion in mouse. 
Tg(ElkPrP) is transgenic line 5037, expressing elk PrPc in knockout background 
mouse. Tg(BoPrP) is transgenic line 3705, expressing bovine PrPc in knockout 
background mouse. Tg(HuPrP-M129) is transgenic line 6816, expressing human 
PrPC with amino acid methiomine in 129 in knockout background mouse. 
Tg(HuPrP-V129) is transgenic line 7826, expressing human PrPc with amino acid 
valine in 129 in knockout background mouse. S.Hamster is syrian hamster brain 
homogenate, 10µl from 10% brain homogenate (A) No treatment (B) samples 
were treated with beta-Mercaptoethanol (C) samples were treated with PNGase F 
only. (D) Samples were treated with beta-Mercaptoethanol and PNGase F. These 
blots were probed with 7H11.
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Figure 2.14 Prion protein sequence alignment of various mammals and 
shuffle PrP #68 in order to assess 7H11 epitope. Numbers at top indicate 
mouse number amino acids sequence. The glycosylation sites are designated by 
green hexagons, and highlighted in green boxes. The black bars at the bottom 
indicate secondary structure, partial -helix 1, -sheet 2, -helix 2 and partial 
-helix 3 sequentially. Disulfide bridge which linked -helix 2 and -helix 3 is 
indicated in red lines.  According to the western blot analysis, mAb 7H11 failed to 
recognize bovine PrP (cow) which has a unique amino acid is located between 
two N-linked glycosylation sites.  Amino acids labeled with red circle indicate the 
potential epitope of 7H11. 
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4) Monoclonal Antibody 9H9 
In western blots analysis, the mAb 9H9 reacted with 10% Tg mouse brain 
homogenates expressing mouse PrP and Tg (McerB+C), but did not react with 
cervid PrP, bovine PrP, ovine PrP, equine PrP and human PrP (Fig 2.15A).  MAb 
9H9 also recognized PrP in Syrian hamster brain homogenate, but did not react 
with mink PrP, ferret PrP, squirrel monkey PrP and cow PrP (Figure 2.15B, 
performed by Dr. Jason Bartz lab).  Based on the western blot analysis of Tg 
mouse homogenates and brain homogenates of other mammals, mAb 9H9 is 
specific to mouse and Syrian hamster PrP.  Comparing the sequences of various 
mammals and shuffled PrP #68, we conclude that the epitope of mAb 9H9 is at 
the C-terminus of mouse PrP (Fig 2.16). 
 
Table 2 shows the summary of our in-house monoclonal antibodies reactivity with 
various species.  
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Figure 2.15 Western blot analysis of assessing 9H9 epitope via brain 
homogenate of (A)Tg mice and (B)mammals. (A) 50 ug transgenic mice brain 
homogenate was loaded in each lane. This blot is probed with 9H9. The 
secondary antibody is anti-mouse in 1:5000 dilution.  Reactivity is seen with 
mouse and chimeric PrP only. (B) This blot was done by Dr. Jason Bartz Lab. 
500ug brain was loaded in each lane.Each lane is reprsented hamster, mink, 
ferret, squirrel monkey and cow sequentially.  Only hamster shows reactivity.
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Figure 2.16 Prion protein sequence alignment of various mammals and 
shuffled PrP #68 in order to assess 9H9 epitope. Numbers at top indicate 
mouse sequence number.  According to western blot analysis, mAb 9H9 only 
has reactivity with mouse and Syrian hamster. Blue box is showing the unique 
sequence in mouse and hamster is same as our immunogen, shuffled PrP #68. 
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Table 2 summary of mAbs reactivity with various species 
 5C6 9E9 7H11 9H9 
Mouse + - + √ 
Deer + + + - 
Elk + + + - 
Bovine + + - - 
Ovine ARQ + + + - 
Ovine VRQ - + + - 
Equine + + + - 
Human M129 + - Weak - 
Human V129 + - Weak - 
Hamster + ND ND + 
Mink + ND ND - 
Ferret + ND ND - 
Squirrel Monkey - ND ND - 
“-“indicates no reactivity. “+” indicates positive reactivity. ND indicates not 
determined. 
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Section 2: Epitope tagging 
 
As described in the introduction, pathogenesis in prion diseases is mediated by 
abnormal folding of prion protein from alpha-helix rich form PrPC to beta-sheet rich 
form PrPSc.  Unfortunately, the mechanism of conversion from PrPC to PrPSc is 
still unclear.  Since we have generated these novel monoclonal antibodies, we 
can utilize them, in conjunction with epitope tagging, to track PrPC trafficking 
which could elucidate the conversion process.  We also can confirm these 
monoclonal antibodies epitopes by insertion or elimination of the epitopes 
predicted in section 1.  All mutated PrPs were created via mutagenesis and 
transfected into rabbit kidney epithelial cells (RK13 cell) which do not express 
endogenous PrPC.  Table 3 shows a summary of the constructs we made derived 
from elk, mouse, and bovine PrP and their reactivity to our in-house monoclonal 
antibodies.  
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Table 3. Summary of constructs derived from elk, mouse, and bovine PrP 
and their reactivity to various monoclonal antibodies. 
 Elk Mouse Bovine 
 + - + - + - 
5C6 wild type A133V wild type A132V wild type N/A 
  N162S  N158S   
9E9 wild type 93G 93G wild type N/A N/A 
7H11 N/A N/A  Q185E E197Q  
     E197Q-H166Y  
9H9 QR230DGRR wild type wild type N/A N/A wild type 
  QR230RR     
  QR230DGRR     
 
Table 3. The top row indicates the PrP species from which the constructs are 
derived.  The second row indicates positive (+) or non (-) reactivity of the 
constructs to the mouse monoclonal antibodies indicated on the left (5C6, 9E9, 
7H11, 9H9).  ‘Wild type’ indicates the original PrP of the species in the 
corresponding column.  ‘N/A’ indicates data not available.  Substitution mutant 
nomenclature is as follows: ‘A133V’ indicates that Alanine in 133rd position in elk 
PrP is substituted with Valine.  Addition of a residue is described as follows:  
‘93G’ indicates that a Glycine was inserted after the 93rd position in elk PrP.  
Deletion of a residue is described as follows: ‘93G’ indicates that a Glycine was 
deleted from the 93rd position of mouse PrP. 
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A. The substitution of residue 132 in mouse PrP affects the susceptibility of 
RML infection in cell culture model  
Mutating the proposed amino acids of the 5C6 epitope is one way to confirm that 
these amino acids are required for 5C6 recognition.  As described in result 
section 1, the epitope of mAb 5C6 is located at amino acids 132 alanine and 158 
asparagine (in mouse numbering) (Figure 2.6).  In order to differentiate various 
PrPs we eliminated the 5C6 epitope by mutating the alanine to valine at residue 
132, or asparagine to serine at residue 158 in mouse PrP.  These constructs are 
referred to as MoPrP-A132V and MoPrP-N158S.  The corresponding amino 
acids were mutated in elk PrP to eliminate the 5C6 epitope: alanine to valine at 
residue 133 or asparagine to serine at residue 162.  These constructs are 
referred to as ElkPrP-A133V and ElkPrP-N162S.  To generate stable cell lines 
expressing PrPs of interest, RK13 cells were transfected with wild type mouse PrP, 
MoPrP-A132V, MoPrP-N158S, wild type elk PrP, elkPrP-A133V or elkPrP-N162S 
cloned into a pIRES-puro3 vector.  All cell lines expressing a PrPC with a mutated 
5C6 epitope could be detected by mab 6H4 (Figure 3.1A).  However, only wild 
type PrP, but not mutated PrPs could be detected by mAb 5C6 (Figure 3.1B).  
These results demonstrate that the mutated constructs were successfully 
expressed in the RK13 cells and that mutation of either alanine or asparagine is 
sufficient to abolish 5C6 recognition.  It also confirmed the epitope of mAb 5C6 
we described in section 1.  
 
In order to determine susceptibility of the mutated mouse PrP or elk PrP in RK 13 
cells to prions, we infected these cells with appropriate strains: mouse-adapted 
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RML scrapie prions in the case of cells expressing MoPrP variants and CWD 
isolate bala05 in the case of cells expressing elkPrP variants.  The infected 
cultures were passaged three times in order to reduce detectable PrPSc from 
infection.  Previous experiment showed infection of cells with RML or CWD 
resulted in detectable PrPSc, however, there is a progressive reduction of PrPSc 
after repeated passage (Bian, Napier et al. 2010).  To analyze mouse PrPSc and 
elk PrPSc by western blotting, detergent extracts containing equal amounts of 
protein were treated with PK and centrifuged for 1 hour at 100,000 x g.  This high 
speed centrifugation pelleted insoluble PrPSc molecules.  We used proteinase K 
to detect the PrPSc formation in culture.  In mouse cell lines, we detected PrPSc 
molecules in wild type mouse PrP after treating cultures with mouse-adapted RML 
scrapie prions but not in the RK13 cells expressing empty pIRES vector.  Mouse 
PrPC with an amino acid switch from asparagine to serine does not affect the 
conversion ability from mouse PrPC to mouse PrPSc.  However substituting 
alanine to valine at residue 132 in mouse PrP affects the susceptibility to RML 
(Figure 3.2).  In elk cell lines, no PrPSc was detected in mutated elk PrP 
constructs but wild type elk PrP (Figure 3.3) did show PrPSc formation.  
Substituting alanine with valine in mouse PrP at position 132 affects mouse PrPSc 
formation and substituting the same position in elk PrP also affects elk PrPSc 
formation.  The residue 132 in mouse PrP corresponding to residue 136 in sheep 
PrP is a polymorphism in sheep PrP.  A previous report showed that sheep with 
valine at residue 136 had higher susceptibility to scrapie compared to sheep with 
alanine at residue 136 (Acin, Martin-Burriel et al. 2004).  This indicated that the 
alanine at residue 132 in mouse PrP might be involved in the conversion of PrPC 
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to PrPSc and also implicated it as a residue responsible for the species barrier 
between mouse and sheep.  Substituting asparagine with serine in mouse PrP at 
position 158 does not affect mouse PrPSc formation but substituting the same 
position in elk PrP affects elk PrPSc formation.  This indicated these residues are 
species specific. 
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Figure 3.1 Western blot analysis of RK13 cells expressing mutated elk or 
mouse PrP to assess 5C6 reactivity. To assess the 5C6 epitope, the potential 
epitope was introduced or eliminated from elk or mouse constructs. The 
constructs were cloned into pIRES-Puro3 and transfected into rabbit kidney cells 
(RK13) that do not express endogenous PrP. RK-Vector is negative control 
expressing pIRES vector only. RK-MoPrP denotes RK13 cells expressing full 
length of mouse PrP. RK-ElkPrP denotes RK13 cells expressing full length elk PrP. 
RK-ElkPrP-A133V denotes RK13 cells expressing elk PrP with substitution 
alanine to valine at residue 133. RK-ElkPrP-N162S denotes RK13 cells 
expressing elk PrP with substitution arginnine to cystine at residue 162. 
RK-MoPrP-A132V denotes RK13 cells expressing mouse PrP with substitution 
alanine to valine at residue 132. RK-MoPrP-N158S denotes RK13 cells 
expressing mouse PrP with substitution arginnine to cystine at residue 158. 
Membranes were probed with (A) mouse monoclonal Ab 6H4 at 1:10,000 dilution 
and (B) mouse monoclonal Ab 5C6 at 1:20 dilution. Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 3.2 Western blot analysis of conversion ability of mutated mouse PrP 
expressed in RK13 cells.  To detect the ability of PrPC to PrPSc conversion in 
mutated mouse PrPs, the cells were infected with RML brain homogenate. RKV is 
negative control expressing pIRES vector in RK13 cells. RKM denotes RK13 cells 
expressing full length of mouse PrP. RKM-A132V denotes RK13 cells expressing 
mouse PrP with substitution alanine to valine at residue 132. RKM-N158S 
denotes RK13 cells expressing mouse PrP with substitution arginnine to cystine 
at residue 158. The first six lanes are the cell lines without infection. All lines were 
challenged with 0.1% RML brain homogenate. Cell lysates were collected with 
cold lysis buffer from 10 cm culture plate at passage 3. Total protein content was 
measured by bicinchoninic acid assay (BCA). Cell lysates detergent extracts 
containng equal amounts protein were treated with 30 mg/ml PK for 1 hr at 37C 
and centrifuge for 1 h at 100,000 x g. Membranes were probed with mouse 
monoclonal Ab 6H4 at 1:10,000 dilution . Secondary antibody: HRP-conjugated 
anti-mouse (GE) at 1:5,000 dilution.  Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 3.3 Western blot analysis of conversion ability of mutated elk PrP in 
RK13 cells. To detect the ability of PrPC to PrPSc conversion in new construct, the 
cells were infected with CWD brain homogenate isolate Bala 05. RKV is negative 
control expressing pIRES vector in RK13 cells. RKE denotes RK13 cells 
expressing full length elk PrP. RKE-A133V denotes RK13 cells expressing elk PrP 
with substitution alanine to valine at residue 133. RKE-N162S denotes RK13 cells 
expressing elk PrP with substitution arginnine to cystine at residue 162. The first 
six lanes show the cell lines without infection. Those cell lines indicated were 
infected with 1/% CWD brain homogenate isolate Bala 05. Cell lysates were 
collected with cold lysis buffer from 10 cm culture plate at passage 3. Cell lysates 
were collected with cold lysis buffer from 10 cm culture plate at passage 3. Total 
protein content was measured by bicinchoninic acid assay (BCA). Cell lysates 
detergent extracts containng equal amounts protein were treated with 30 mg/ml 
PK for 1 hr at 37C and centrifuge for 1 h at 100,000 x g. Membranes were probed 
with mouse monoclonal Ab 6H4 at 1:10,000 dilution . Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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B. The deletion of residue 93 in mouse PrP affects the susceptibility of RML 
infection in cell culture model 
Based on the previous western blot analysis, mAb 9E9 is specific to the C2 
fragment and has narrow specificity for cervid PrP (Figure 2.9).  The epitope for 
9E9 appears to be comprised of GQGGTH in elk and deer PrP.  Mouse PrP at 
the same location has the sequence of GQGGGTH.  There is one extra glycine 
in mouse PrP.  To confirm that this epitope constituted the 9E9 recognition 
sequence we introduced an extra G in elk PrP and eliminated the corresponding 
G in MoPrP via mutagenesis.  We supposed that glycine at residue 93 in mouse 
PrP interrupts 9E9’s binding with mouse PrP.  We successfully transfected and 
expressed all wild type PrPs and variants in RK13 cells as seen via blotting with 
mAb 6H4 (Figure 3.4A).  All PrPC can be detected by mAb 6H4 indicating all 
successfully.  Mouse PrP with one glycine deletion at position 93 was recognized 
by mAb 9E9, and elk PrP with one glycine insertion at same position did not react 
with mAb 9E9 (Figure 3.4B).  This result showed that this extra glycine in mouse 
PrP inhibits 9E9 recognition.    
 
We also would like to determine the susceptibility of the established cell lines to 
prions.  The cell lines expressing elk and mouse PrPC and their mutated 
counterparts were also infected with appropriate strains in order to assess the 
ability of mutated PrPC to be converted to PrPSc.  RML inoculums were used to 
infect cells expressing mouse PrP and its mutant, and CWD inoculums were used 
to infect cells expressing cervid PrP and its mutant.  All the samples were 
prepared as described in previous studies.  Consistent with the 5C6 result in 
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mutated elk cell lines, we did not observe PrPSc from cells expressing elk PrP with 
the insertion of glycine but did see conversion in wild type elk PrP (Figure 3.5).  
However, we did detect the PrPSc from cells expressing mutated mouse PrP 
containing 9E9 epitope and wild type mouse PrP(Figure 3.6).  Interestingly, we 
could not detect the diglycosylated form of PrPSc in the mutated mouse PrP which 
contained the 9E9 epitope.  These results demonstrated that an extra glycine in 
mouse PrP sequence is sufficient to interrupt 9E9 recognition.  Producing 9E9 
epitope by deleting this one extra glycine in mouse PrP does not prevent 
formation of mouse PrPSc but decreases formation of di-glycosylated PrPSc.  
Inserting one extra glycine at position 93 in elk PrP both interferes with 9E9 
recognition and affects elk PrPSc formation.  
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Figure 3.4 Western blot analysis of RK13 cells expressing mutated elk or 
mouse PrP to assess 9E9 reactivity To assess the 9E9 epitope, the potential 
epitope was introduced or eliminated from elk or mouse constructs. The 
constructs were cloned into pIRES-Puro3 and transfected into rabbit kidney cells 
that do not express endogenous PrP.  RK-Vector is negative control expressing 
pIRES vector only. RK-MoPrP denotes RK13 cells expressing full length of mouse 
PrP. RK-ElkPrP denotes RK13 cells expressing full length elk PrP. 
RK-ElkPrP-93G denotes RK13 cells expressing elk PrP with a glycine after 
residue 93. RK-MoPrP-93G denotes RK13 cells expressing mouse PrP with 
glycine deletion at residue 93. Membranes were probed with (A) mouse 
monoclonal Ab 6H4 at 1:10,000 dilution and (B) mouse monoclonal Ab 9E9 at 1:5 
dilution.  Secondary antibody: HRP-conjugated anti-mouse (GE) at 1:5,000 
dilution. Blots were developed with chemiluminescence (GE) and visualized via 
Fuji scanner  
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Figure 3.5 Western blot analysis of conversion ability of mutated elk PrP in 
RK13 cells. To assess the ability of PrPC to convert to PrPSc , the transfected cells 
were infected with CWD brain homogenate isolate Bala 05. RK-V is negative 
control expressing pIRES vector in RK13 cells. RKE denotes RK13 cells 
expressing full length elk PrP. RKE-93G denotes RK13 cells expressing elk PrP 
with a glycine after residue 93. The first four lanes indicate cell lines without CWD 
infection. Those cell lines indicated were infected with 1/% CWD brain 
homogenate isolate Bala 05. Cell lysates were collected with cold lysis buffer from 
10 cm culture plate at passage 3. Total protein content was measured by 
bicinchoninic acid assay (BCA). Cell lysates detergent extracts containng equal 
amounts protein were treated with 30 mg/ml PK for 1 hr at 37C and centrifuge for 
1 h at 100,000 x g. Membranes were probed with mouse monoclonal Ab 6H4 at 
1:10,000 dilution. Secondary antibody: HRP-conjugated anti-mouse (GE) at 
1:5,000 dilution.  Blots were developed with chemiluminescence (GE) and 
visualized via Fuji scanner  
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Figure 3.6 Western blot analysis of conversion ability of mutated mouse PrP 
in RK13 cells. To detect PrPC to PrPSc conversion in new constructs, the cells 
were infected with transgenic mice adapted RML brain homogenate. The 
constructs were cloned into pIRES-Puro3 and transfected into rabbit kidney cells 
that do not express endogenous PrP.  RKV is negative control expressing pIRES 
vector in RK13 cells. RKM denotes RK13 cells expressing full length of mouse 
PrP. RKM-93G denotes RK13 cells expressing mouse PrP with glycine deletion 
at residue 93. The first four lanes indicate cell lines without RML infection. Those 
cell lines indicated were infected with 0.1% RML brain homogenate. Red square 
indicates the location of diglycosylated PrP. Cell lysates were collected with cold 
lysis buffer from 10 cm culture plate at passage 3. Total protein content was 
measured by bicinchoninic acid assay (BCA). Cell lysates detergent extracts 
containng equal amounts protein were treated with 30 mg/ml PK for 1 hr at 37C 
and centrifuge for 1 h at 100,000 x g. Membranes were probed with mouse 
monoclonal Ab 6H4 at 1:10,000 dilution Secondary antibody: HRP-conjugated 
anti-mouse (GE) at 1:5,000 dilution.  Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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C. Confirmation of potential epitope of mAb 7H11 and mAb 9H9  
In section 1, we found 7H11 could not recognize bovine PrP and has weaker 
reactivity with human PrP.  We also found the binding ability of 7H11 was 
affected by N-linked oligosaccharides and disulfide bridge.  Based on these 
results, we hypothesized the epitope of mAb 7H11 is located at residue 166 and 
197 of BoPrP.  To further ascertain the recognition site of mAb 7H11, we mutated 
BoPrP at residue 197 from glutamic acid to glutamine.  This construct was 
referred to BoPrP-E197Q.  This residue is unique in bovine PrP sequence 
compare to other mammals PrP sequence and our immunogen.  The 
corresponding amino acids were also mutated from glutamine to glutamic acid at 
residue 185 in mouse PrP to eliminate the 7H11 epitope.  This construct was 
referred to MoPrP-Q185E.  These two mutated constructs were cloned into 
pIRES-Puro3 vector and used to generat cell lines in RK13 cells.  Bovine 
PrP-E197Q and mouse PrP-Q185E were examined via western blot with mAb 
7H11.  As expected, mAb 7H11 lost its affinity for mouse PrP when the 
substitution at 185 was made.  Mutating Bovine PrP to the mouse sequence at 
residue 197 (bovine numbering) did not confer 7H11 binding.  Ongoing studies 
are investigating the importance of amino acid 166 (bovine numbering) in the 
ability of mAb 7H11 to recognize Bovine PrP.   
 
In the previous mapping results, the epitope of mAb 9H9 is located at the 
C-terminus of mouse PrP (Figure 2.16).  The unique amino acid sequence of 
mouse and Syrian hamster PrP in the C-terminus is DGRRS which coincides with 
the immunogen used to generate our antibodies, shuffled PrP#68.  In the same 
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region of other mammals’ PrPs, the amino sequence is QRG.  To clarify the 
binding site of 9H9 and generate a cervid cell line that could be recognized by 
mAb 9H9, three mutant cervid RK13 cell lines were generated by mutating QR to 
DGRR, RR or DGQR starting from residue 230 based on the alignment of 
mammalian PrP.  These constructs are referred to as ElkPrP-QR230DGRR, 
ElkPrP-QR230RR, and ElkPrP-QR230DGQR.  We substituted residue 230Q and 
231R in elk PrP sequence to DGRR to make the sequence the same as mouse 
PrP and our immunogen.   To define the 9H9 recognition site more precisely, two 
other constructs were generated, ElkPrP-QR230RR, and ElkPrP-QR230DGQR.    
All mutated constructs and wild type were expressed successfully in RK13 cells 
as seen via western blotting with mAb 6H4 (Figure 3.7A).  Only one mutant, 
QR230DGRR, showed reactivity with mAb 9H9, but it was extremely weak (Figure 
3.7B). In figure 3.7A, mutated elk PrPs have lower expression levels as compared 
to wild type elk PrP.  In our previous experience, mAb 9H9 has low affinity with 
cell culture samples.  The low expression level of the mutated elk PrPs in RK13 
cells coupled with 9H9’s low affinity with cell culture samples could explain the 
weak reactivity seen in figure 3.7B.  However, it is also possible that there are 
other amino acids which might be involved in the reactivity of 9H9.  The serine in 
the extreme C- terminus might be necessary for 9H9 binding.  
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Figure 3.7 Western blot analysis of RK13 cells expressing mutated elk or 
mouse PrP to assess 9H9 reactivity. Monoclonal antibody 9H9 has a specific 
reactivity with mouse and Syrian hamster. To assess the 9H9 epitope, the 
proposed epitope was introduced into elk constructs. The constructs were cloned 
into pIRES-Puro3 and transfected into RK13 rabbit kidney cells that do not 
express endogenous PrP. RK-Vector indicates negative control expressing pIRES 
vector in the RK13. RK-ElkPrP denotes RK13 cells expressing full length of elk 
PrP.  RK-ElkPRP-QR230DGRR denotes RK13 cells expressing elk PrP with 
amino acids substitution QR with DGRR from residue 230. RK-ElkPrP-QR230RR 
is RK13 cell expressing elk PrP with amino acids substitution with QR with RR 
from residue 230. RK-ElkPrP-QR230DGQR denotes RK13 cell expressing elk 
PrP with amino acids substitution QR with DGQR from residue 230. Membranes 
were probed with (A) mouse monoclonal Ab 6H4 at 1:10,000 dilution and (B) 
mouse monoclonal Ab 9H9. Secondary antibody: HRP-conjugated anti-mouse 
(GE) at 1:5,000 dilution. Blots were developed with chemiluminescence (GE) and 
visualized via Fuji scanner  
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Section 3: Structure analysis via deletion  
 
Despite having the same sequence, PrPC and PrPSc are quite different both 
structurally and biochemically.  To elucidate the mechanism of conversion of 
PrPC to PrPSc has being a long-standing goal in prion disease research.  
Conformational change from PrPC to PrPSc results in a higher percentage of beta 
sheet structure and increased protease resistance.  In an attempt to acquire 
information from PrP’s primary structure regarding conformational changes during 
conversion, we generated a series of ten contiguous amino acids deletion 
constructs spanning amino acids 107 to 230 to find out which region is involved in 
the conformational change (Figure 4.1).  Amino acids 107 to 230 in mouse PrP is 
a region containing secondary structure and post-modifications.  I used these 
previously generated deletion constructs for mapping our novel monoclonal 
antibodies.  Figure 4.1 shows the scheme of the serial deletion constructs we 
made and the location of glycosylation sites and cysteines involved in disulfide 
bonding.  Also it indicates what secondary structure is lacking in each deletion 
construct.  All the deletion constructs were made via mutagenesis and cloned 
into pIRES-puro3 vector (Invitrogen).  These constructs were transfected into RK 
13 cells and expression was checked via immunoblotting with monoclonal 
antibody R1 (Figure 4.2).  R1 was generated by immunization with PrP 
liposomes and recognizes residues 225 to 230 in the C-terminus of PrP 
(Williamson, Peretz et al. 1998).  In other words, R1 recognized all the deletion 
constructs except MoPrP222-230 which includes recognition site of R1.  One of 
the N-linked oligosaccharide sites is in the deletion mutant 192-201and has been 
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removed; therefore this mutant has lower molecular weight than other deletion 
mutants.  When we analyzed these cell lines with mAb 6H4, not only the deletion 
which encompasses its epitope site, but also other deletions in the central region 
of construct lacked reactivity (Figure 4.3).  Most of the deletions from 141 to 221 
have no reactivity with mAb 6H4, Only MoPrP182-191 and MoPrP192-201 
have very weak reactivity.  Based on sections 1 and 2, we know the epitope of 
mAb 5C6 is at residue 132 and 158 of MoPrP.  Therefore, we expected there to 
be no reactivity with MoPrP132-141 or MoPrP152-161.  Surprisingly,  
constructs with deletions ranging  from 121 to 221 showed no recognition with 
mAb 5C6 (Figure 4.4).    We continued to analyze our in-house monoclonal 
antibodies with these constructs expressing in RK 13 cells.  MAb 9E9 is does not 
detect mouse PrP, so we did not use for analysis.  The 7H11 epitope is stericially 
hindered by N-linked oligosaccharides and 7H11 binding is increased in the 
presence of the disulfide bond.  7H11 has two epitopes, residue 154 and 185 (in 
mouse numbering) (Figure2.14).  We observed hindrance effects in 
MoPrP141-151 to MoPrP211-221 with 7H11 (Figure 4.5).  As we expected, 
MAb 9H9 recognized all the deletion constructs excepting MoPrP222-230 which 
contains the 9H9 epitope.  Only antibodies with epitopes in the C-terminus of PrP 
meet our expectation that the antibody will recognize all deletions except for that 
which encompasses its epitope.  
 
We wondered if post-translational modifications in mammalian cells could 
influence the antibody binding capacity in our deletion constructs.  To address 
this question, we transferred all deletion constructs into pET-100 vector and 
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expressed them in a bacterial system.  In the bacterial system, there is no 
post-translational modification, but proteins do form secondary structure and 
disulfide bonds.  Since the 6H4 epitope lies somewhere between amino acids 
144 and 152 we hypothesized that the deletion mutants 142-151 and 152-161 
would not be recognized by 6H4.  As we expected, mAb 6H4 recognized all the 
constructs excepted for deletions including the binding region in the bacterial 
system (Figure 4.7).  However, when we detected these constructs with other 
antibodies, we observed an epitope shielding phenomenon, as in the mammalian 
system.  In the western blot, most of the deletion constructs with deletions from 
the central region of 132 to 221 had no reactivity with mAb 5C6 (Figure 4.8).  
Only MoPrP182-191 had slight reactivity with 5C6.  When analyzing mAb 7H11 
with these constructs in bacterial system, 7H11 recognized wild type recombinant 
mouse PrP and some deletion constructs but did not have reactivity with the 
constructs containing deletions close to the 7H11 epitope (Figure 4.9).  MAb 9H9 
recognized wild type PrP and all the deletion constructs except MoPrP222-230, 
just as in the mammalian cells (Figure 4.10).  However, the binding reactivity of 
9H9 with recombinant protein is stronger than it is with mammalian cell lysates.  
Comparing western blots probed with 9H9 or other monoclonal antibodies, we 
confirmed the binding site of 9H9 is located in the C-terminus of PrP.  Since mAb 
5C6 recognizes alanine at position 132 and asparagines at position 158 in mouse 
PrP, it is a conformation dependent monoclonal antibody, as is 7H11.  Routinely, 
before performing gel electrophoresis, all samples are mixed with denaturing 
reagents like sodium dodecyl sulfate (SDS), an anionic detergent which 
denatures secondary and non–disulfide–linked tertiary structures, and applies a 
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negative charge to each protein in proportion to its mass. Traditional wisdom 
dictates that conformation dependent monoclonal antibodies cannot detect 
proteins which are denatured.  However, in our western blot results, we can 
detect wild type mouse PrP with our conformation dependent monoclonal 
antibodies, 5C6 and 7H11.  That indicates that the structured region of PrP forms 
a very stable structure that cannot be denatured by a detergent like SDS.  The 
eptiopes of 9H9 or R1 are in the unstructured C-terminus region, which can be 
recognized.  
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Figure 4.1 The scheme of the serial deletion constructs  
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Figure 4.2 Western blot analysis of serial deletion constructs in mammal 
cell line with R1. All deletion constructs were cloned into pIRES-Puro3 and 
transfected into RK13 cells. Cell lysates were collected with cold lysis buffer from 
10 cm culture plate. Total protein content was measured by bicinchoninic acid 
assay (BCA).  Each well was loaded 50ug cell lysate. Membrane was probed 
with anti-PrP R1 at 1:10,000 dilution which epitope is 225 to 230. Secondary 
antibody: HRP-conjugated anti-human (pierce) at 1:5,000 dilution.  Blots were 
developed with chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 4.3 Western blot analysis of serial deletion constructs in mammal 
cell line with 6H4. All deletion constructs were cloned into pIRES-Puro3 and 
transfected into RK13 cells. Each well was loaded 50µg cell lysate. Membrane 
was probed with anti-PrP 6H4 with 1:10000 dilutions which epitope is from 144 to 
152.  Secondary antibody: HRP-conjugated anti-mouse (GE) at 1:5,000 dilution.  
Blots were developed with chemiluminescence (GE) and visualized via Fuji 
scanner  
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Figure 4.4 Western blot analysis of serial deletion constructs in mammal 
cell line with 5C6. All deletion constructs were cloned into pIRES-Puro3 and 
transfected into RK13 cells. Each well was loaded 50µg cell lysate. Membrane 
was probed with mouse monoclonal Ab 5C6 at 1:20 dilution. Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 4.5 Western blot analysis of serial deletion constructs in mammal 
cell line with 7H11. All deletion constructs were cloned into pIRES-Puro3 and 
transfected into RK13 cells. Each well was loaded 75µg cell lysate. Membrane 
was probed with mouse monoclonal Ab 7H11 without dilution. Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution.  Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 4.6 Western blot analysis of serial deletion constructs in mammal 
cell line with 9H9. All deletion constructs were cloned into pIRES-Puro3 and 
transfected into RK13 cells. Each well was loaded 75µg cell lysates. Membrane 
was probed with mouse monoclonal Ab 9H9 without dilution. Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution.  Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 4.7 Western blot analysis of serial deletion constructs in bacterial 
system via 6H4. All deletion constructs were cloned into pET-100 and 
transformed into BL21. Seed 1:50 dilution overnight bacterial broth and grow until 
OD 600 reach 0.6. Added 1mM IPTG into broth and grew for 4 hours. Collected 1 
ml induced bacteria cell lysate and mixed with 100 µl 1X loading buffer.  Each 
well was loaded 5µl cell lysate. Membrane was probed with anti-PrP 6H4 with 
1:10000 dilutions which epitope is from 144 to 152. Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution.  Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 4.8 Western blot analysis of serial deletion constructs in bacterial 
system via 5C6. All deletion constructs were cloned into pET-100 and 
transformed into BL21. Each well was loaded 5µl cell lysate. Membrane was 
probed with mouse monoclonal Ab 5C6 with 1:20 dilution. Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution.  Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 4.9 Western blot analysis of serial deletion constructs in bacterial 
system via 7H11. All deletion constructs were cloned into pET-100 and 
transformed into BL21. Each well was loaded 5µl cell lysate. Membrane was 
probed with mouse monoclonal Ab 7H11 without dilution. Secondary antibody: 
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution.  Blots were developed with 
chemiluminescence (GE) and visualized via Fuji scanner  
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Figure 4.10 Western blot analysis of serial deletion constructs in bacterial 
system via 9H9. All deletion constructs were cloned into pET-100 and 
transformed into BL21. Lane 1 is expressing pET-Vector in BL-21.  Each well 
was loaded 5 µl cell lysate. Membrane was probed with mouse monoclonal Ab 
9H9 without dilution. Secondary antibody: HRP-conjugated anti-mouse (GE) at 
1:5,000 dilution.  Blots were developed with chemiluminescence (GE) and 
visualized via Fuji scanner  
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Chapter 4 
Discussion 
 
Prions are transmitted in an unconventional way via a protein particle without 
nucleic acids.  It is still mysterious and many aspects are as yet unknown.    
Most anti-PrP antibodies are expensive.  Conformational change is a major 
component in the mechanism of prion replication.  The two forms of PrP share 
the same amino acid sequence, but have drastically different biochemical 
properties.  In an attempt to acquire more information on the conversion process, 
such as key sites, we created novel sequences containing mouse and elk PrP via 
shuffling of the two species’ PrP DNA sequences. In the hopes that we could 
generate new and novel prion antibodies to answer some of the mysteries 
surrounding the conversion process, we used three of our shuffled DNA 
constructs as immunogen for in-house antibody production. These three 
constructs were selected for producing immunogen, because their equences are 
distributed equally between mouse and elk PrP.  Using these new PrP 
sequences which mixed mouse and elk PrP, we generated a series of monoclonal 
antibodies with novel epitopes.  We collected all the hybridoma cells generated 
by three shuffled PrP with novel sequence.  Each shuffled PrP produced thirty to 
fifty hybridoma cells.  We only screened those hybridoma cells generated by 
shuffled PrP#68.  Four novel mAbs have been characterized and each of them 
has unusual and useful properties.  They are 5C6, 9E9, 7H11 and 9H9.  
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MAb 5C6 reacts efficiently with PrPs from a broad range of mammalian species 
including mouse, deer, elk, bovine, equine, human, Syrian hamster, mink, ferret, 
and sheep with alanine in residue 136.  According to the sequence of sheep 
(VRQ) and squirrel monkey, residues 132 alanine and 158 asparagine are 
necessary for 5C6 binding.  We confirmed this when we substituted alanine with 
valine at position 132 or asparagine with serine at position 158 in mouse PrP and 
the same position in elk PrP.  There are 26 amino acids between these two 
binding sites.  This indicated that 5C6 is a conformation dependent mAb.  
These two recognition sites span the base of the loop between 1 and 2 and are 
close to each other when the protein is folded.  To investigate the role of the 5C6 
epitope, we expressed these mutated mouse PrP variants or mutated elk PrP 
variants in the RK13 cells and infected with proper prions.  Substituting alanine 
with valine in mouse PrP at position 132 affects mouse PrPSc formation and 
substituting the same position in elk PrP also affects elk PrPSc formation. Residue 
132 in mouse PrP corresponds to residue 136 in sheep PrP.  This residue is also 
one polymorphism of sheep PrP.  A previous report showed that sheep PrP with 
valine at residue 136 has higher susceptibility to scrapie compared to sheep PrP 
with alanine at residue 136 (Acin, Martin-Burriel et al. 2004).  That indicated the 
alanine at residue 132 in mouse PrP might be involved in the conversion of PrPC 
to PrPSc and might be the amino acid that results in the species barrier between 
mouse and sheep.  To prove this assumption, we can infect the cell line, 
RK-MoPrPA132, with sheep scrapie.  If this cell line can be infected by sheep 
scrapie, then it indicates residue 132 in mouse PrP is the key site for species 
barrier between sheep and mouse or other mammals.  It is possible because 
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most other mammals PrP sequence have alanine at that position.  Substituting 
asparagine with serine in mouse at position 158 does not affect mouse PrPSc 
formation but substituting the same position in elk PrP affects elk PrPSc formation.  
This indicated these residues are species specific.  Even when expressing the 
same amino acid in the same position, it shows a species specific role.  Since 
this substitution does not affect mouse PrPSc formation, it would be useful to use 
this 5C6 epitope negative mouse PrP in the scrapie cell assay (Klohn, Stoltze et al. 
2003; Bian, Napier et al. 2010).  We coule differentiate the wild type and mutated 
form by using our novel mAb 5C6.  
 
MAb 9E9 has narrow specificity and only has strong affinity for cervid PrP.  It has 
less affinity with horse and sheep PrP.  It might be influenced by the amino acid 
serine after glycine at position 93, because in elk PrP and our immunogen 
shuffled PrP #68, there is threonine after glycine at position at 92. 9E9 epitope is 
adjacent to C2 cleavage site; an extra glycine in mouse PrP sequence interrupts 
the 9E9 recognition.  It was confirmed when we deleted glycine in mouse PrP at 
position 93 or inserted one glycine at the same position in elk PrP.  When we 
produced the 9E9 epitope by deleting one glycine in mouse PrP, it did not prevent 
formation of mouse PrPSc but decreased formation of di-glycosylated PrPs.  
Does the 9E9 tag in this mutated mouse PrP influence the PK digestion site?  
Several studies suggest that either helix 1 (residues 144–154) or the 90–145 part 
of the PrP protein plays a critical role in the conversion process to a β-sheet 
structure (Peretz, Williamson et al. 1997; Zhang, Stockel et al. 1997; Glockshuber, 
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Hornemann et al. 1998; Morrissey and Shakhnovich 1999).  It would be 
interesting to engineer a transgenic mouse with this 9E9-postive mouse PrP and 
inoculate with mouse prion.  Inserting one glycine at position 93 in elk PrP affects 
elk PrPSc formation.  This indicated that the sequence between C1 and C2 
cleavage sites might be involved in the conversion of PrPC to PrPSc 
 
The binding ability of mAb 7H11 is sterically affected by the secondary structure of 
PrP.  It recognizes mouse, elk, deer, and sheep and has weak affinity to human 
PrP.  It does not recognize bovine PrP.  The binding capacity of 7H11 was 
affected by the presence of two N-linked glycans and the disulfide bond.  
According to these results, we supposed one of the epitopes of mAb 7H11 is 
between the two N-linked glycosylation sites, the other epitope is located 30 
amino acids away in the upstream of the sequence.  This indicated that 7H11 is 
also a conformation dependent mAb.  We do not have more results to assure the 
exact recognition site of 7H11 at this stage.  
MAb 9H9 has narrow species specificity since it only reacts with mouse and 
hamster PrP.  We only know this antibody recognized the end of C-terminus PrP 
and it has mouse specificity.  If we can clarify the exact residues, it could be a 
great tool to study mouse PrP.       
To further understand the mechanism of conversion and characterize the 
structure of Prions, we generated an array of mutated PrPs with contiguous ten 
amino acids deletion constructs across the structured region of PrP (amino acids 
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107 to 230).  This region contains the alpha-helix, beta-sheet, and 
post-translational modifications like glycosylation.  These deletion constructs 
provide a way to map our novel monoclonal antibodies.  The western blot 
analysis gave us the surprising result that the folded structure of wild type PrP is 
ultra-stable, even when we treated our sample with a detergent like SDS and ran 
our gel under denaturing conditions.  If we deleted 10 amino acids within the 
c-terminal region, it caused instability in the structure and had effects on antibody 
recognition.   
We created four novel mAbs and each of them has unusual and useful properties.  
We can study prion replication from these novel epitopes.  They will be helpful in 
studying prion pathogenesis.  
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